Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL427229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL326516 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12658449 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL4064991 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3727 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL6027558 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL2619251 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0189629-A1 | Method of treatment of viral diseases in plants utilizing ribavirin | VIRATEK, INC. (US) | 1986-08-06 | — | — | EP | claimed |
| CN-110658279-B | Method for detecting ribavirin and metabolites thereof in livestock and poultry hair | 江西省农业科学院农产品质量安全与标准研究所 | 2022-07-15 | — | — | CN | disclosed |
| CN-112725227-B | Sponge-derived streptomyces and preparation and application of active substance for inhibiting hexokinase II | 中国科学院沈阳应用生态研究所 | 2022-07-05 | — | — | CN | disclosed |
| US-20190336443-A1 | Ready-To-Use Liquid Parenteral Formulations Of Ribavirin | PROVIDENT BANK | 2019-11-07 | — | — | US | disclosed |
| US-20070071720-A1 | Method of treating hepatitis B viral infection | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
| US-20050053625-A1 | Method of treating viral infections | BLOCK TIMOTHY M (US) | 2005-03-10 | — | — | US | disclosed |
| US-6660749-B2 | Administering a dideoxy-imino-glucitol | CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2003-12-09 | — | — | US | disclosed |
| US-20030130317-A1 | Inhibition of glycolipid biosynthesis | UNITHER VIROLOGY, LLC | 2003-07-10 | — | — | US | disclosed |
| CN-1290168-A | Inhibition of membrane-associated viral replication | UNIV OXFORD (GB) | 2001-04-04 | — | — | CN | disclosed |
| EP-0054432-B1 | USE OF 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDES FOR THE MANUFACTURE OF MEDICAMENTS INHIBITING MALIGNANT TUMORS | VIRATEK, INC. (US) | 1990-01-31 | — | — | EP | disclosed |
| EP-0181050-A2 | 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide for use in medical treatment of humans | VIRATEK, INC. (US) | 1986-05-14 | — | — | EP | disclosed |
| US-4138547-A | Process for preparing 1,2,4-triazole nucleosides | ICN PHARMACEUTICALS, INC. (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130317-A1 | Inhibition of glycolipid biosynthesis | UGCG, GBA1, UGGT1 | LMNA 1546/4885SMN1; SMN2 2457/4885ALDH1A1 599/4885 |
| US-20190336443-A1 | Ready-To-Use Liquid Parenteral Formulations Of Ribavirin | SARS1, TTPA, TST | LMNA 2455/4885SMN1; SMN2 261/4885ALDH1A1 3791/4885 |
| US-20070071720-A1 | Method of treating hepatitis B viral infection | IFNG, IFNAR1, HAVCR2 | LMNA 3922/4885SMN1; SMN2 4497/4885ALDH1A1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.